🇺🇸 FDA
Pipeline program

TAK-007

TAK-007-1001

Phase 1 mab terminated

Quick answer

TAK-007 for Refractory Lupus Nephritis is a Phase 1 program (mab) at Takeda with 1 ClinicalTrials.gov record(s).

Program details

Company
Takeda
Indication
Refractory Lupus Nephritis
Phase
Phase 1
Modality
mab
Status
terminated

Clinical trials